Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Arthritis Rheumatol. 2016 May;68(5):1262–1271. doi: 10.1002/art.39558

Figure 2. Anti-IFI16 antibody levels in cases and controls.

Figure 2

Anti-IFI16 antibody levels are significantly higher in patients with scleroderma and digital gangrene (n=39) than in scleroderma controls with Raynaud’s and no history of digital ischemic events (maximum Raynaud’s Medsger severity score of 1) (n=39) (p=0.02).